156 related articles for article (PubMed ID: 26677455)
1. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.
Johnson JA; Feeney ER; Kubiak DW; Corey GR
Open Forum Infect Dis; 2015 Dec; 2(4):ofv156. PubMed ID: 26677455
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oritavancin and nisin alone and their combination against vancomycin resistant enterococci strains in hospitalized patients in Turkiye.
Sefali S; Y N
Indian J Med Microbiol; 2024; 47():100489. PubMed ID: 37890415
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment.
Di Cecco C; Monticelli J; Di Bella S; Di Maso V; Luzzati R
J Chemother; 2024 Feb; 36(1):31-34. PubMed ID: 37602423
[TBL] [Abstract][Full Text] [Related]
4. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
[TBL] [Abstract][Full Text] [Related]
5. Catheter-Associated Vancomycin-Resistant Enterococcus faecium Ventriculitis and Multidrug-Resistant Acinetobacter baumannii Pneumonia With Subsequent Acinetobacter Ventriculitis: A Case Report.
Rei KM; Reddy V; Andraos C; Brazdzionis J; Siddiqi J
Cureus; 2023 Nov; 15(11):e49058. PubMed ID: 38116362
[TBL] [Abstract][Full Text] [Related]
6. Development of VRE meningitis due to haematogenous spread while on high-dose daptomycin therapy.
Sanikommu S; Lusardi K; Burdine L; Dare RK
JAC Antimicrob Resist; 2023 Dec; 5(6):dlad118. PubMed ID: 38021040
[TBL] [Abstract][Full Text] [Related]
7. Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.
Moenster RP; Wallace-Lacey A; Western H; Tiefenaur S; Abdulbasir A; Alberts J; Doty J; Abner H; Skouby D; Lorenz M; Fong R; Arora J; Linneman TW
Open Forum Infect Dis; 2023 Nov; 10(11):ofad411. PubMed ID: 37937043
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience.
Brownell LE; Adamsick ML; McCreary EK; Vanderloo JP; Ernst EJ; Jackson ER; Schulz LT
Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):13-19. PubMed ID: 32592120
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
[TBL] [Abstract][Full Text] [Related]
10. Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples.
Fernández-Natal I; Sáez-Nieto JA; Medina-Pascual MJ; Albersmeier A; Valdezate S; Guerra-Laso JM; Rodríguez H; Marrodán T; Parras T; Tauch A; Soriano F
New Microbes New Infect; 2013 Dec; 1(3):35-40. PubMed ID: 25356327
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement.
Van Hise NW; Petrak RM; Shah K; Diaz M; Chundi V; Redell M
Infect Dis Ther; 2024 Mar; 13(3):535-547. PubMed ID: 38421519
[TBL] [Abstract][Full Text] [Related]
12. Infective Endocarditis Due to High-Level Gentamicin-Resistant
Tong K; Luo H; Dai H; Huang W
Infect Drug Resist; 2024; 17():2329-2335. PubMed ID: 38882654
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.
Si S; Durkin MJ; Mercier MM; Yarbrough ML; Liang SY
Infect Dis Clin Pract (Baltim Md); 2017 Mar; 25(2):105-107. PubMed ID: 28428726
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.
Baiardi G; Cameran Caviglia M; Piras F; Sacco F; Prinapori R; Cristina ML; Mattioli F; Sartini M; Pontali E
Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887199
[TBL] [Abstract][Full Text] [Related]
15. Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations.
Bongiovanni M; Thoueille P; Barda B; Mercier T; Marzolini C; Ramponi N; Choong E; Cantù M; Decosterd LA; Bernasconi E
Eur J Clin Microbiol Infect Dis; 2024 May; ():. PubMed ID: 38740656
[No Abstract] [Full Text] [Related]
16. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
Brade KD; Rybak JM; Rybak MJ
Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
[TBL] [Abstract][Full Text] [Related]
17. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
Stewart CL; Turner MS; Frens JJ; Snider CB; Smith JR
Infect Dis Ther; 2017 Jun; 6(2):277-289. PubMed ID: 28386776
[TBL] [Abstract][Full Text] [Related]
18. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
19. Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach.
VanEperen AS; Segreti J
J Infect Chemother; 2016 Jun; 22(6):351-9. PubMed ID: 27066882
[TBL] [Abstract][Full Text] [Related]
20. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.
Jensen IS; Lodise TP; Fan W; Wu C; Cyr PL; Nicolau DP; DuFour S; Sulham KA
Clin Drug Investig; 2016 Feb; 36(2):157-68. PubMed ID: 26692006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
